CEO Clive Meanwell has been with The Medicines Co. (TMC) for 22 years, most of that as its CEO, but as its search for a new identity in recent years has dragged on, the firm’s board of directors apparently determined that new leadership was necessary. Mark Timney, formerly the CEO of Purdue Pharma LP, will succeed Meanwell, although the long-time CEO will remain with the company as chief innovation officer.
The Medicines Co. Names Mark Timney As CEO In A Shakeup
CEO Clive Meanwell helped to shape the company over his nearly 22 years at the helm, including when it marketed a portfolio of hospital-based drugs. Now the company is solely focused on shepherding the PCSK9 inhibitor inclisiran to the finish line.

More from Leadership
The challenging US biosimilar market remains a persistent problem, leading the biosimilar developer to reconsider how it invests in the future while pushing for changes.
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
More from Scrip
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.
AstraZeneca remains committed to investing in R&D and alliances in China, where Susan Galbraith, the UK major’s head of oncology R&D, sees innovation eventually reaching parity with the US and Europe.